[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Cadir B, Karahan N, Nasir S, Aydin MA, Turkaslan SS: Unusual synchronous presentation of maxillary sinus fibrosarcoma and gemistocytic astrocytoma with a complication called leukocytoclastic vasculitis: a case report. Eur J Dent; 2009 Jul;3(3):233-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual synchronous presentation of maxillary sinus fibrosarcoma and gemistocytic astrocytoma with a complication called leukocytoclastic vasculitis: a case report.
  • We report synchronous presentation of maxillary sinus fibrosarcoma and gemistocytic astrocytoma which is, to our knowledge, unique in the literature.
  • Both tumors metastases to other organ rarely and the metastatic spread of gemistocytic astrocytoma to fibrosarcoma or vice versa have also not been reported in the literature yet.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 1998 Jul;34(4):292-6 [9813725.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):201-7 [8318414.001]
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):1-7 [1624288.001]
  • [Cites] Br J Oral Maxillofac Surg. 1992 Apr;30(2):115-8 [1567797.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):399-406 [1993905.001]
  • [Cites] Medicine (Baltimore). 1988 Jul;67(4):220-30 [3292873.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1700-11 [10547542.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Arthritis Care Res. 2000 Dec;13(6):417-23 [14635319.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1495-503 [11745227.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Feb;34(1):269-81 [11344078.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3735-41 [11268447.001]
  • [Cites] Eur J Surg Oncol. 2000 Mar;26(2):145-8 [10744932.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):198-200 [3276633.001]
  • (PMID = 19756200.001).
  • [ISSN] 1305-7456
  • [Journal-full-title] European journal of dentistry
  • [ISO-abbreviation] Eur J Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC2741197
  • [Keywords] NOTNLM ; Fibrosarcoma / Gemistocytic astrocytoma / Leukocytoclastic vasculitis / Maxillary sinus / Radiotherapy / Synchronous cancer
  •  go-up   go-down


2. Ahmed N, Bhurgri Y, Sadiq S, Shakoor KA: Pediatric brain tumours at a tertiary care hospital in Karachi. Asian Pac J Cancer Prev; 2007 Jul-Sep;8(3):399-404
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The morphological distribution of cases was astrocytoma (28 cases, 34.6%), primitive neuroectodermal tumor or PNET (40 cases; 49.4%), ependymoma (8 cases, 10%), mixed glioma (4 cases; 5%) and a case of oligodendroglioma.
  • The morphological categorization of supratentorial tumors was astrocytoma (17 cases; 63%), ependymoma (5 cases; 18.5%), mixed glioma (2 cases; 7.4%).
  • The 17 supratentorial astrocytoma were sub-categorized as follows - pilocytic astrocytoma (5 cases; 29.4%), grade II astrocytoma (6 cases; 35.3%); grade III astrocytoma (2 cases; 11.8%), anaplastic astrocytoma (1 case; 5.9%) and glioblastoma multiforme (3 cases; 17.7%).
  • The morphological categorization of infratentorial tumors was astrocytoma (11 cases; 20.4%), medulloblastoma (38 cases; 70.4%), ependymoma (3 cases; 5.6%) and mixed glioma - astroependymoma (2 cases, 3.7%).
  • The morphological sub-categorization of infratentorial astrocytoma was pilocytic astrocytoma (7 cases, 63.6%), with gemistocytic astrocytoma, grade II, grade III and anaplastic astrocytoma comprising 1 (9.1%) case each.
  • There is a predominance of medulloblastoma and a paucity of astrocytomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159977.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


3. Suzuki T, Izumoto S, Fujimoto Y, Maruno M, Ito Y, Yoshimine T: Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion. J Clin Pathol; 2005 Feb;58(2):166-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: GC tumour cells can be divided into two types, those mainly composed of strongly GFAP and L1 positive gemistocytic cells, the other composed of small, GFAP and L1 negative spindle shaped cells.
  • CONCLUSION: The strong expression of L1 in patients with GC and its poor expression in the 20 patients with other types of glioma, including those with GFAP positive gemistocytic astrocytomas, suggest that L1 expression may play a role in the histogenesis of GC.
  • [MeSH-minor] Adult. Aged. Antibodies, Neoplasm / analysis. Astrocytoma / chemistry. Astrocytoma / pathology. Brain Chemistry. Cell Division / physiology. Female. Glial Fibrillary Acidic Protein / analysis. Glioblastoma / chemistry. Glioblastoma / pathology. Humans. Immunohistochemistry / methods. Ki-67 Antigen / immunology. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2001 Sep;12(9):2699-710 [11553709.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2935-40 [9679949.001]
  • [Cites] Lancet. 2003 Sep 13;362(9387):869-75 [13678974.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):28880-8 [15128735.001]
  • [Cites] Nature. 1983 Sep 29-Oct 5;305(5933):427-30 [6621692.001]
  • [Cites] Nature. 1985 Aug 22-28;316(6030):725-8 [2412126.001]
  • [Cites] Clin Neuropathol. 1985 Jul-Aug;4(4):135-48 [4053456.001]
  • [Cites] J Cell Biol. 1987 Oct;105(4):1893-9 [2444603.001]
  • [Cites] Development. 1988 Apr;102(4):639-55 [3048970.001]
  • [Cites] Surg Neurol. 1991 Dec;36(6):431-40 [1759182.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10752-8 [1587850.001]
  • [Cites] Neuroreport. 1992 Jun;3(6):481-4 [1391752.001]
  • [Cites] Neurosci Lett. 1992 Sep 14;144(1-2):221-4 [1436706.001]
  • [Cites] J Neurosci. 1993 Nov;13(11):4764-75 [8229197.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Mol Cell Biol. 1995 Apr;15(4):1942-52 [7891688.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1440-4 [8640837.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):13-7 [9577364.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):661-73 [11706054.001]
  • (PMID = 15677537.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Neural Cell Adhesion Molecule L1
  • [Other-IDs] NLM/ PMC1770574
  •  go-up   go-down


Advertisement
4. Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR: Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine; 2010 Apr 26;28(19):3371-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy.
  • Gemistocytic astrocytoma (GemA) is a low-grade glioma that typically progresses to lethal malignancy despite conventional therapies.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Clin Invest. 2007 May;117(5):1184-94 [17476348.001]
  • [Cites] Vet Immunol Immunopathol. 2007 Mar 15;116(1-2):69-78 [17224188.001]
  • [Cites] J Neurooncol. 2007 Jun;83(2):121-31 [17077937.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4541-4 [17510377.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1405-16 [17535971.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1756-63 [17582604.001]
  • [Cites] J Exp Med. 2007 Oct 1;204(10):2473-85 [17893201.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):133-48 [17874037.001]
  • [Cites] J Immunother. 2007 Nov-Dec;30(8):789-97 [18049330.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):147-56 [18202698.001]
  • [Cites] Mol Ther. 2008 Mar;16(3):618-26 [18180770.001]
  • [Cites] Neurosurg Rev. 2008 Apr;31(2):141-55; discussion 155 [18259789.001]
  • [Cites] J Gene Med. 2008 Apr;10(4):329-39 [18220319.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] Curr Protoc Neurosci. 2008 Oct;Chapter 4:Unit 4.23 [18972378.001]
  • [Cites] Eur J Immunol. 2008 Oct;38(10):2665-77 [18958874.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] J Immunother. 2009 Feb-Mar;32(2):186-94 [19238018.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6113-27 [19789315.001]
  • [Cites] J Am Anim Hosp Assoc. 2000 Jan-Feb;36(1):43-50 [10667405.001]
  • [Cites] Vaccine. 2009 Oct 19;27(44):6210-6 [19699331.001]
  • [Cites] J Neuroimmunol. 2010 Jan 25;218(1-2):134-9 [19900722.001]
  • [Cites] Cancer Gene Ther. 2002 Nov;9(11):925-34 [12386831.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1172-9 [14520441.001]
  • [Cites] Nat Med. 2003 Nov;9(11):1377-82 [14528297.001]
  • [Cites] Vet Pathol. 2003 Nov;40(6):659-69 [14608019.001]
  • [Cites] Vet Pathol. 2004 Jan;41(1):10-9 [14715963.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):777-82 [15252850.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] J Am Vet Med Assoc. 1986 Apr 15;188(8):851-6 [3710874.001]
  • [Cites] J Vet Intern Med. 1988 Apr-Jun;2(2):71-4 [3221360.001]
  • [Cites] Gan No Rinsho. 1989 Sep;35(11):1255-60 [2681871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5705-9 [8202551.001]
  • [Cites] J Vet Intern Med. 1991 Jul-Aug;5(4):219-26 [1941756.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):399-406 [1993905.001]
  • [Cites] Am J Vet Res. 1994 Aug;55(8):1086-92 [7978647.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):525-31 [9046311.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Curr Opin Immunol. 2005 Aug;17(4):434-40 [15950444.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):456-9 [15906353.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):175-83 [16132490.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5770-6 [17020983.001]
  • [Cites] Exp Hematol. 2006 Nov;34(11):1451-61 [17046564.001]
  • [Cites] Cancer Gene Ther. 2007 Jun;14(6):550-60 [17415381.001]
  • (PMID = 20197146.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS054193; United States / NINDS NIH HHS / NS / IR21-NS055738; United States / NINDS NIH HHS / NS / R21 NS055738; United States / NINDS NIH HHS / NS / NS055738-01A2; United States / NINDS NIH HHS / NS / 1R01-NS 057711; United States / NINDS NIH HHS / NS / U01 NS052465; United States / NCI NIH HHS / CA / R01 CA160782; United States / NINDS NIH HHS / NS / R21 NS055738-01A2; United States / NINDS NIH HHS / NS / 1UO1 NS052465; United States / PHS HHS / / 1R21-NSO54143; United States / NINDS NIH HHS / NS / R01 NS042893; United States / NINDS NIH HHS / NS / 1 RO1 NS 054193; United States / NINDS NIH HHS / NS / R01 NS 42893; United States / NINDS NIH HHS / NS / R01 NS057711
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Neoplasm; 0 / CPG-oligonucleotide; 0 / Cell Extracts; 0 / Oligodeoxyribonucleotides; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS190873; NLM/ PMC2854671
  •  go-up   go-down


5. Arvanitis LD, Koukoulis GK, Kanavaros P: The expression of the O-linked N-acetylglucosamine containing epitope H in the gemistocytic, pilocytic and subependymal giant cell astrocytomas. Oncol Rep; 2009 Sep;22(3):521-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of the O-linked N-acetylglucosamine containing epitope H in the gemistocytic, pilocytic and subependymal giant cell astrocytomas.
  • In normal human brains the epitope H is present mostly to a minority of fibrous astrocytes, whereas it is greatly up-regulated in reactive astrocytes and is increased in well differentiated fibrillary astrocytomas compared to anaplastic astrocytomas and glioblastomas.
  • In this study the expression of the epitope H was investigated in thirty cases of gemistocytic (WHO grade II), pilocytic (WHO grade I), and subependymal giant cell (WHO grade I) astrocytomas using the mAbH with the indirect immunoperoxidase method.
  • The ten cases of gemistocytic astrocytomas revealed an overall high expression pattern.
  • The ten cases of pilocytic astrocytomas revealed a biphasic pattern of epitope H expression.
  • The ten cases of subependynal giant cell astrocytomas occurring in tuberous sclerosis revealed an overall high expression pattern.
  • This study shows that there is high expression of the epitope H in gemistocytic, pilocytic and subependymal giant cell astrocytomas.
  • Collectively considering, the present and our previous data, it appears that there is a spectrum of the expression levels of the epitope H ranging from the high expression in the reactive astrocytes and low grade astrocytomas to the low/null expression in the normal astrocytes and glioblastomas.
  • [MeSH-major] Acetylglucosamine / analysis. Astrocytoma / chemistry. Brain Neoplasms / chemistry. Epitopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639198.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Epitopes; V956696549 / Acetylglucosamine
  •  go-up   go-down


6. Nowak-Sadzikowska J, Gliński B, Szpytma T, Pluta E: Postoperative irradiation of incompletely excised gemistocytic astrocytomas. Clinical outcome and prognostic factors. Strahlenther Onkol; 2005 Apr;181(4):246-50
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative irradiation of incompletely excised gemistocytic astrocytomas. Clinical outcome and prognostic factors.
  • BACKGROUND AND PURPOSE: Although gemistocytic astrocytomas are considered slow-growing tumors, they often behave aggressively and carry the least favorable prognosis among low-grade astrocytomas.
  • The aim of this study is to evaluate the outcomes and prognostic factors of patients with incompletely excised gemistocytic astrocytomas irradiated postoperatively.
  • PATIENTS AND METHODS: Records of 48 patients with incompletely excised gemistocytic astrocytoma, irradiated between 1976 and 1998 at the Department of Radiation Oncology, Maria Skłodowska-Curie Memorial Cancer Center, Cracow, Poland, were reviewed.
  • CONCLUSION: In most patients with gemistocytic astrocytoma, combined surgery and postoperative radiotherapy result in only short-term survival.
  • Older age is the most important unfavorable prognostic factor in patients with gemistocytic astrocytoma.
  • [MeSH-major] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827694.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Tihan T, Vohra P, Berger MS, Keles GE: Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective. J Neurooncol; 2006 Jan;76(2):175-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective.
  • Gemistocytic astrocytoma still continues to be enigmatic; both in terms of definition and prognostic implications.
  • The currently accepted definition of gemistocytic astrocytoma requires 20% or more gemistocytes, and considers the neoplasm as a diffuse astrocytoma, which is a WHO grade II tumor.
  • Some suggest that gemistocytic morphology should be considered as evidence of a higher grade astrocytoma.
  • There is still a need for studies with sufficient numbers of well-matched gemistocytic and non-gemistocytic astrocytic neoplasms to decide whether upgrading a tumor with 'significant' number of gemistocytes is justifiable.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132490.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 39
  •  go-up   go-down


8. Geranmayeh F, Scheithauer BW, Spitzer C, Meyer FB, Svensson-Engwall AC, Graeber MB: Microglia in gemistocytic astrocytomas. Neurosurgery; 2007 Jan;60(1):159-66; discussion 166
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microglia in gemistocytic astrocytomas.
  • OBJECTIVE: Although gemistocytic astrocytomas are graded as World Health Organization II astrocytomas, they behave more aggressively than other astrocytomas.
  • Microglial cells, a feature of this astrocytoma variant, are of increasing interest in the context of glioma growth.
  • METHODS: We selected 23 tumor biopsies from 201 samples obtained from patients with gemistocytic astrocytomas operated at Mayo Clinic between 1985 and 1998.
  • RESULTS: A high number of microglia was detected in gemistocytic astrocytomas.
  • More microglia were present if the fraction of gemistocytic tumor cells was high (correlation coefficient = 0.699; P < 0.0002).
  • CONCLUSION: Our results support the view that gemistocytic astrocytomas contain unusually high numbers of microglial cells.
  • We propose that the finding of aberrant MHC Class II expression by gemistocytic tumor cells correlates with a loss of immune-competent MHC Class II-expressing microglia.
  • This may be related to the especially poor prognosis of gemistocytic astrocytomas for which induction of T cell anergy could provide one explanation.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Microglia / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228265.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Avninder S, Sharma MC, Deb P, Mehta VS, Karak AK, Mahapatra AK, Sarkar C: Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations--a study of 32 cases. J Neurooncol; 2006 Jun;78(2):123-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations--a study of 32 cases.
  • Gemistocytic astrocytomas (GAs) are a distinct variant of astrocytomas, generally classified as WHO grade II, and are associated with an aggressive biological behavior.
  • Immunoreactivity for CD3 (T-cells), CD20 (B-cells) and CD68 (macrophages) were evaluated to characterize the perivascular inflammatory infiltrates, while p53, epidermal growth factor receptor (EGFR), cyclin D1 and p27-immunolabeling were studied to analyze the tumor biology.Overall, the mean gemistocytic index in the study was 39.6% (range, 12.2-80.8%), with multinucleation in gemistocytes and mitosis being present in 56.2% and 15.6% respectively.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Giant Cells / pathology. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614946.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


10. Kim SH, Lee KG, Kim TS: Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma. Acta Cytol; 2007 May-Jun;51(3):375-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma.
  • OBJECTIVE: To evaluate the squash smear features of subependymal giant cell astrocytoma (SEGA) in comparison with gemistocytic astrocytoma and giant cell glioblastoma.
  • STUDY DESIGN: We compared the squash smear features of 3 cases of SEGA, 9 cases of gemistocytic astrocytoma and 3 cases of giant cell glioblastoma with the morphometric findings.
  • While the gemistocytic astrocytoma had several tumor cells showing a vertically located nucleus, the tumor cells of SEGA showed nuclei oriented mainly in parallel.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology


11. Nozaki M, Ohnishi A, Fujimaki T, Nagashima K, Cho K, Sawamura Y: Congenital gemistocytic astrocytoma in a fetus. Childs Nerv Syst; 2006 Feb;22(2):168-71
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital gemistocytic astrocytoma in a fetus.
  • This report presents a case of a congenital gemistocytic astrocytoma diagnosed by antenatal intrauterine ultrasound.
  • The histological study revealed gemistocytic astrocytoma (WHO grade II).
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Fetus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1994 Mar;10(2):104-10 [8033157.001]
  • [Cites] AJR Am J Roentgenol. 1990 Sep;155(3):587-93 [2167004.001]
  • [Cites] J Neuropathol Exp Neurol. 1964 Apr;23:280-92 [14137675.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10 ):556-9 [9403206.001]
  • [Cites] Neuroradiology. 1982;23 (5):267-74 [7121821.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(12):1213-22 [9932120.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):604-9 [3047342.001]
  • [Cites] Lab Invest. 1997 Feb;76(2):277-84 [9042164.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):399-406 [1993905.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):227-8 [15193038.001]
  • [Cites] Surg Neurol. 1984 Jun;21(6):597-609 [6372141.001]
  • [Cites] P R Health Sci J. 2002 Mar;21(1):43-5 [12013680.001]
  • [Cites] Fetal Diagn Ther. 2003 May-Jun;18(3):137-9 [12711864.001]
  • [Cites] Childs Brain. 1981;8(4):263-70 [7261690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):171-8 [10758320.001]
  • [Cites] Med Pediatr Oncol. 1994;22(5):309-17 [8127254.001]
  • [Cites] Childs Nerv Syst. 1999 Apr;15(4):197-201 [10361971.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Pediatr Neurosurg. 2002 Nov;37(5):267-70 [12411720.001]
  • [Cites] Childs Nerv Syst. 2000 Aug;16(8):501-2 [11007501.001]
  • [Cites] J Neurosurg. 1951 May;8(3):315-9 [14841542.001]
  • [Cites] J Neurooncol. 1998 May;37(3):263-70 [9524084.001]
  • [Cites] Ultrasound Obstet Gynecol. 1995 Jan;5(1):63-6 [7850596.001]
  • (PMID = 15864706.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Synaptophysin
  •  go-up   go-down


12. Varlet P, Jouvet A, Miquel C, Saint-Pierre G, Beuvon F, Daumas-Duport C: [Criteria of diagnosis and grading of oligodendrogliomas or oligo-astrocytomas according to the WHO and Sainte-Anne classifications]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):239-46
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Criteria of diagnosis and grading of oligodendrogliomas or oligo-astrocytomas according to the WHO and Sainte-Anne classifications].
  • According to this approach, the SA classification includes in the category of oligodendrogliomas, the fibrillary or gemistocytic diffuse astrocytomas (WHO grade II) as well as a substantial proportion of astrocytomas WHO grade III, 2) the WHO uses multiple histological criteria for the grading of oligodendrogliomas (grade II versus grade III), including the degree of differentiation, cellular atypia, mitotic activity and necrosis.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / pathology. Brain Neoplasms / classification. Brain Neoplasms / pathology. Oligodendroglioma / classification. Oligodendroglioma / pathology. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292167.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Aloisio F, Levine JM, Edwards JF: Immunohistochemical features of a feline spinal cord gemistocytic astrocytoma. J Vet Diagn Invest; 2008 Nov;20(6):836-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical features of a feline spinal cord gemistocytic astrocytoma.
  • A gemistocytic astrocytoma is described in the spinal cord of a 3-year-old, spayed, female, Domestic Shorthair cat.
  • The increased expression of p53 in the neoplasm was suggestive of an abnormal biological behavior of the p53 protein and its possible involvement in the neoplastic process of feline astrocytoma.
  • [MeSH-major] Astrocytoma / veterinary. Cat Diseases / pathology. Spinal Cord Neoplasms / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987242.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Martins DC, Malheiros SM, Santiago LH, Stávale JN: Gemistocytes in astrocytomas: are they a significant prognostic factor? J Neurooncol; 2006 Oct;80(1):49-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemistocytes in astrocytomas: are they a significant prognostic factor?
  • Our aim was to retrospectively evaluate the influence of gemistocytic astrocytes, cellular proliferation indices, immunoexpression of proteins p53 and bcl-2 in the clinical outcome of 39 patients with WHO grade II and III astrocytomas with the presence of gemistocytes.
  • Our finding confirms recent reports that question the role of gemistocytes as a prognostic factor in diffuse astrocytomas.
  • The significance and role of gemistocytes in astrocytomas has yet to be defined and warrants further study.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645716.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


15. Tirabosco R, De Maglio G, Skrap M, Falconieri G, Pizzolitto S: Expression of the Polycomb-Group protein BMI1 and correlation with p16 in astrocytomas an immunohistochemical study on 80 cases. Pathol Res Pract; 2008;204(9):625-31
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the Polycomb-Group protein BMI1 and correlation with p16 in astrocytomas an immunohistochemical study on 80 cases.
  • To gain a new insight, we tested 80 primary brain astrocytomas for BMI1 expression using immunohistochemistry and established a correlation with the expression of p16, a negatively regulated target of BMI1 function.
  • Slight non-significant differences were noted in the expression profile between grades II, III, and IV astrocytomas.
  • However, when the 22 BMI1 + /p16+ tumors were examined cytologically, a substantial proportion contained a significant gemistocytic component, which is thought to be an adverse prognostic factor or to display a high degree of anaplasia, suggesting a common molecular mechanism of BMI1/p16 pathway disruption, which may have prognostic implications.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Nuclear Proteins / biosynthesis. Proto-Oncogene Proteins / biosynthesis. Repressor Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18450386.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


16. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol; 2005 Jun;64(6):479-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While survival rates for pilocytic astrocytomas were excellent (96% at 10 years), the prognosis of diffusely infiltrating gliomas was poorer, with median survival times (MST) of 5.6 years for low-grade astrocytoma WHO grade II, 1.6 years for anaplastic astrocytoma grade III, and 0.4 years for glioblastoma.
  • TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but infrequent (13%) in oligodendrogliomas.
  • LOH 1p/19q typically occurred in tumors without TP53 mutations and were most frequent in oligodendrogliomas (69%), followed by oligoastrocytomas (45%), but were rare in fibrillary astrocytomas (7%) and absent in gemistocytic astrocytomas.
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Loss of Heterozygosity. Oligodendroglioma. Tumor Suppressor Protein p53 / genetics


17. Takei H, Florez L, Bhattacharjee MB: Cytologic features of subependymal giant cell astrocytom: a review of 7 cases. Acta Cytol; 2008 Jul-Aug;52(4):445-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of subependymal giant cell astrocytom: a review of 7 cases.
  • OBJECTIVE: To describe the cytologic features of subependymal giant cell astrocytoma (SEGA) on smears and analyze cytomorphologic parameters that may help in reaching the diagnosis of SEGA.
  • CONCLUSION: The cytologic features of SEGA are highly characteristic and thus are of great use in supporting a diagnosis of SEGA and in excluding mimics, primarily gemistocytic astrocytoma and ependymoma.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Lateral Ventricles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18702362.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Reyaz N, Tayyab M, Khan SA, Siddique T: Correlation of glial fibrillary acidic protein (GFAP) with grading of the neuroglial tumours. J Coll Physicians Surg Pak; 2005 Aug;15(8):472-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 35 cases of various grade astrocytoma showed a varying intensity of GFAP staining.
  • Similarly, 3 cases of glioblastoma multiforme, 2 cases of sub-ependymal giant cell astrocytoma, 2 cases of pleomorphic xanthoastrocytoma, 2 out of 4 cases of ependymoma and the case of oligoastrocytoma showed a positive reaction.
  • The stain was more intense over processes than in perikaryons, with the exception of gemistocytic astrocytomas and the giant cells in glioblastoma multiforme, which showed an equally intense stain over perikaryons and processes.
  • [MeSH-minor] Astrocytoma / metabolism. Astrocytoma / pathology. Child. Female. Humans. Immunoenzyme Techniques. Immunohistochemistry. Male. Neuroglia / metabolism. Oligodendroglioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202357.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


19. Majchrzak K, Bierzyńska-Macyszyn G, Bobek-Billewicz B, Majchrzak H, Ładziński P: Rare primary tumours of the hypothalamus in adults: clinical course and surgical treatment. Neurol Neurochir Pol; 2010 Nov-Dec;44(6):546-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 2 patients with craniopharyngiomas located exclusively in the third ventricle, and single patients with gemistocytic astrocytoma, Langerhans cell histiocytosis X and hamartoma of the hypothalamus each.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21225516.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


20. Mobasheri MB, Jahanzad I, Mohagheghi MA, Aarabi M, Farzan S, Modarressi MH: Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. Cancer Detect Prev; 2007;31(4):296-302

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • But, SYCP3 transcripts were found in four tumor samples (moderately differentiated gemistocytic astrocytoma, pituitary adenoma, glioma and an ovarian tumor).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920210.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Proteins; 0 / SYCP3 protein, human; 0 / TSGA10 protein, human
  •  go-up   go-down


21. Buccoliero AM, Franchi A, Castiglione F, Gheri CF, Mussa F, Giordano F, Genitori L, Taddei GL: Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology; 2009 Feb;29(1):25-30
Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study.
  • Subependymal giant-cell astrocytoma (SEGA) is a rare intra-ventricular low-grade tumor which frequently occurs as a manifestation of tuberous sclerosis complex.
  • In spite of this, in the recently revised WHO classification of the CNS tumors, SEGA has been still included in the group of astrocytomas.
  • Histologically, tumors were composed of three types of cells: spindle, gemistocytic and ganglion-like.
  • [MeSH-major] Astrocytoma / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564101.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


22. Daumas-Duport C, Koziak M, Miquel C, Nataf F, Jouvet A, Varlet P: [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):247-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Definition of homogeneous tumor groups of oligodendrogliomas or oligo-astrocytomas is a basic condition for an adequate evaluation and comparison of the results of treatments in patients from various institutions.
  • PATIENTS AND METHODS: This study included 251 adult patients in whom a SA grade A or B oligodendroglioma or oligo-astrocytoma was newly diagnosed at our institution from 1984 to 2003.
  • Routine histological preparations and post-contrast preoperative MRI/CT-scan were simultaneously reviewed in order to assess the impact on survival of the following features: presence or absence of a polymorphous or gemistocytic astrocytic component, of necrosis and of contrast enhancement (CH); endothelial hyperplasia (EH) assessed as absent, present minor (HE+) or (HE++) when conform to the threshold of HE defined in the SA grading system of oligodendrogliomas.
  • RESULTS: 70.1% of the tumors were classified as "pure" oligodendroglioma, 19.5% as "polymorphous oligo-astroastrocytoma" and 10.3% as "gemistocytic oligo-astrocytoma".
  • In grade A, or B tumors, the presence of a polymorphous or a gemistocytic component had no significant influence on survival; however respectively 53% and 65% of these tumours versus 32% of "pure" oligodendrogliomas were grade B at the time of diagnosis.
  • CONCLUSIONS: From these results and our previous observation that, according to the SA classification of gliomas, only oligodendrogliomas or oligo-astrocytomas may not show CE, we propose that for retrospective studies:.
  • 1) tumors diagnosed according to the Ste-Anne classification as oligodendroglioma or oligo-astrocytoma be regrouped in a unique category, 2) independent of their histological type and grade according to the WHO, gliomas that do not show CE be regrouped with SA oligodendrogliomas grade A, 3) concerning gliomas that show CE on MRI: oligodendrogliomas or oligo-astrocytomas WHO grade II or III, as well as WHO secondary glioblastomas or glioblastomas with an oligodendroglial component, be regrouped with SA oligodendrogliomas grade B; however tumors that show ring-like CE surrounding large foci of necrosis and finger-like "peritumoral" edema should be excluded or analysed separately.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292168.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Salmaggi A, Gelati M, Pollo B, Marras C, Silvani A, Balestrini MR, Eoli M, Fariselli L, Broggi G, Boiardi A: CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. J Neurooncol; 2005 Sep;74(3):287-93
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology revealed 11 fibrillary, 6 protoplasmatic, 5 gemistocytic astrocytoma, 18 oligoastrocytoma and 10 oligodendroglioma.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132525.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC
  •  go-up   go-down






Advertisement